Combining Anti-IL-8, Tasquinimod Treatment, and Blockage of Pyruvate Dehydrogenase in Breast Cancer Immunotherapy

Using immunotherapy to treat breast cancer, one of the most common cancers that affects women and the second most common cancer among women in the United States, has achieved many successes. However, how to solve the problem of cancer resistance to therapies caused by myeloid-derived suppressor cells and immunosuppressive tumor microenvironment remains a major challenge. To improve the performance of immunotherapy, we chose to explore the three putative therapeutic approaches including anti IL 8 antibody injection, PDH inhibition, and the use of tasquinimod, then combining them to observe anti-tumor effects in a murine model. We anticipate the greatest decrease of tumor volume in triple combination, concluding the feasibility of our method on treating breast cancer.